Literature DB >> 7091161

Management of atrial fibrillation in the post-thyrotoxic state.

H K Nakazawa, K Sakurai, N Hamada, N Momotani, K Ito.   

Abstract

This study was designed to investigate the appropriate timing for cardioversion in patients with chronic atrial fibrillation who had been rendered euthyroid from a thyrotoxic state. We carried out a retrospective study of 163 patients with thyrotoxic atrial fibrillation, with a mean follow-up of 34 months. With control of thyroid function alone, 101 patients had spontaneous reversion of atrial fibrillation to sinus rhythm and 62 patients had persistent atrial fibrillation. In those with spontaneous reversion, the longest duration of atrial fibrillation prior to the euthyroid state was 13 months. In those with persistent fibrillation, the shortest duration of atrial fibrillation prior to the euthyroid state was eight months. Almost three-quarters of those with spontaneous reversion had conversion to sinus rhythm within three weeks of becoming euthyroid. No spontaneous reversion occurred if atrial fibrillation was still present after the patients had been in a euthyroid state for four months. This study suggests that spontaneous reversion of atrial fibrillation to sinus rhythm is highly unlikely if the duration of atrial fibrillation before the euthyroid state is achieved exceeds 13 months, or if it is still present after the patient has been in a euthyroid state for four months, Cardioversion should be performed at about the 16th week after the euthyroid state is achieved.

Entities:  

Mesh:

Year:  1982        PMID: 7091161     DOI: 10.1016/0002-9343(82)90850-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  33 in total

Review 1.  Thyrotoxic atrial fibrillation.

Authors:  Malvinder S Parmar
Journal:  MedGenMed       Date:  2005-01-04

Review 2.  Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology.

Authors:  M P Vanderpump; J A Ahlquist; J A Franklyn; R N Clayton
Journal:  BMJ       Date:  1996-08-31

3.  Atrial fibrillation and the pituitary-thyroid axis: a re-evaluation.

Authors:  J C Forfar
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

4.  ATRIAL FIBRILLATION IN THYROTOXICOSIS.

Authors:  M K Garg; K M Hassan; J S Dugal; J S Saini
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 5.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 6.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

7.  Graves' disease and atrial fibrillation: the case for even higher doses of therapeutic iodine-131.

Authors:  G R Scott; J C Forfar; A D Toft
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18

Review 8.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 9.  Arrhythmia and thyroid dysfunction.

Authors:  S Marrakchi; F Kanoun; S Idriss; I Kammoun; S Kachboura
Journal:  Herz       Date:  2014-07-04       Impact factor: 1.443

10.  Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis.

Authors:  Torsten K Roepke; Elizabeth C King; Andrea Reyna-Neyra; Monika Paroder; Kerry Purtell; Wade Koba; Eugene Fine; Daniel J Lerner; Nancy Carrasco; Geoffrey W Abbott
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.